Abstract
This paper summarizes the experience with interferon alpha (IFN alpha) as single-agent therapy and in combination gathered at M.D. Anderson Cancer Center. It also covers some of the laboratory research associated with these clinical studies.
MeSH terms
-
Combined Modality Therapy
-
Cytarabine / therapeutic use
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use*
-
Interferon-gamma / therapeutic use
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Recombinant Proteins
Substances
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Cytarabine
-
Interferon-gamma